These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38955298)

  • 1. A Zanamivir-protein conjugate mimicking mucin for trapping influenza virion particles and inhibiting neuraminidase activity.
    Xue M; Deng A; Wang JN; Mi X; Lao Z; Yang Y
    Int J Biol Macromol; 2024 Jun; 275(Pt 1):133564. PubMed ID: 38955298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oseltamivir modified bovine serum albumin inhibits neuraminidase activity and accumulates virion particles to disturb influenza virus replication.
    Qin HJ; Li S; Zhu YB; Bao YB; Tang Q; Liu WB; Zhong M; Zhao Y; Yang Y
    Carbohydr Res; 2022 Oct; 520():108631. PubMed ID: 35839640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guanidinothiosialoside-Human Serum Albumin Conjugate Mimics mucin Barrier to Restrict Influenza Infection.
    Yu Y; Zhou JP; Jin YH; Wang X; Shi XX; Yu P; Zhong M; Yang Y
    Int J Biol Macromol; 2020 Nov; 162():84-91. PubMed ID: 32522538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic pentatrideca-valent triazolylsialoside inhibits influenza virus hemagglutinin/neuraminidase and aggregates virion particles.
    Lao Z; Li Y; Mi X; Tang Q; Li J; Chen Y; Yang Y
    Eur J Med Chem; 2023 Nov; 259():115578. PubMed ID: 37467617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoenzymatic synthesis of sialyl-α2,3-lactoside-functionalized BSA conjugate inhibits influenza infection.
    Xue M; Tan L; Zhang S; Wang JN; Mi X; Si W; Qiao Y; Lao Z; Meng X; Yang Y
    Eur J Med Chem; 2024 Jun; 276():116633. PubMed ID: 38968785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of eicosavalent triazolylsialoside-conjugated human serum albumin as a dual hemagglutinin/neuraminidase inhibitor and virion adsorbent for the prevention of influenza infection.
    Li Y; Liu HY; Yang MJ; Liu D; Song JQ; Lao Z; Chen Y; Yang Y
    Carbohydr Res; 2023 Oct; 532():108918. PubMed ID: 37586142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiosialoside-decorated polymers use a two-step mechanism to inhibit both early and late stages of influenza virus infection.
    Yu Y; Qin HJ; Shi XX; Song JQ; Zhou JP; Yu P; Fan ZC; Zhong M; Yang Y
    Eur J Med Chem; 2020 Aug; 199():112357. PubMed ID: 32428793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses.
    Tarbet EB; Hamilton S; Vollmer AH; Luttick A; Ng WC; Pryor M; Hurst BL; Crawford S; Smee DF; Tucker SP
    J Antimicrob Chemother; 2014 Aug; 69(8):2164-74. PubMed ID: 24777908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amide-sialoside protein conjugates as neomucin bioshields prevent influenza virus infection.
    Zhong M; Yu Y; Song JQ; Jia TW; Liu AY; Zhao TF; He HJ; Yang MB; Zhang WX; Yang Y
    Carbohydr Res; 2020 Sep; 495():108088. PubMed ID: 32807356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
    Wu Y; Gao F; Qi J; Bi Y; Fu L; Mohan S; Chen Y; Li X; Pinto BM; Vavricka CJ; Tien P; Gao GF
    J Virol; 2016 Dec; 90(23):10693-10700. PubMed ID: 27654293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
    Gubareva LV; Webster RG; Hayden FG
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system.
    Pires de Mello CP; Drusano GL; Adams JR; Shudt M; Kulawy R; Brown AN
    Eur J Pharm Sci; 2018 Jan; 111():443-449. PubMed ID: 29079337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors.
    Tamura D; Sugaya N; Ozawa M; Takano R; Ichikawa M; Yamazaki M; Kawakami C; Shimizu H; Uehara R; Kiso M; Kawakami E; Mitamura K; Kawaoka Y
    Clin Infect Dis; 2011 Feb; 52(4):432-7. PubMed ID: 21248368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymer-attached zanamivir inhibits synergistically both early and late stages of influenza virus infection.
    Lee CM; Weight AK; Haldar J; Wang L; Klibanov AM; Chen J
    Proc Natl Acad Sci U S A; 2012 Dec; 109(50):20385-90. PubMed ID: 23185023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.
    Lv X; Wang P; Li C; Cheng S; Bi Y; Li X
    J Med Chem; 2021 Dec; 64(23):17403-17412. PubMed ID: 34797984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.
    Bauer K; Dürrwald R; Schlegel M; Pfarr K; Topf D; Wiesener N; Dahse HM; Wutzler P; Schmidtke M
    Med Microbiol Immunol; 2012 Feb; 201(1):61-72. PubMed ID: 21688167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuraminidase inhibitor susceptibility profile of human influenza viruses during the 2016-2017 influenza season in Mainland China.
    Huang W; Cheng Y; Li X; Tan M; Wei H; Zhao X; Xiao N; Dong J; Wang D
    J Infect Chemother; 2018 Sep; 24(9):729-733. PubMed ID: 29866491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel I117T substitution in neuraminidase of highly pathogenic avian influenza H5N1 virus conferring reduced susceptibility to oseltamivir and zanamivir.
    Kode SS; Pawar SD; Tare DS; Keng SS; Hurt AC; Mullick J
    Vet Microbiol; 2019 Aug; 235():21-24. PubMed ID: 31282375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza A/H4N2 mallard infection experiments further indicate zanamivir as less prone to induce environmental resistance development than oseltamivir.
    Tepper V; Nykvist M; Gillman A; Skog E; Wille M; Lindström HS; Tang C; Lindberg RH; Lundkvist Å; Järhult JD
    J Gen Virol; 2020 Aug; 101(8):816-824. PubMed ID: 31855133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.
    McKimm-Breschkin J; Trivedi T; Hampson A; Hay A; Klimov A; Tashiro M; Hayden F; Zambon M
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2264-72. PubMed ID: 12821478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.